Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients.

Case reports in transplantation

Hevia V, Gómez V, Alvarez S, Díez Nicolás V, Gómez Del Cañizo C, Orosa A, Galeano Álvarez C, Burgos Revilla FJ.
PMID: 23781380
Case Rep Transplant. 2013;2013:196528. doi: 10.1155/2013/196528. Epub 2013 May 26.

Purpose. Transitional cell carcinoma (TCC) affecting the graft after renal transplantation is a very infrequent way of presentation of this tumor. Our aim is to present our single institution experience with 2 cases, as well as to perform a...

Cite
Hevia V, Gómez V, Alvarez S, et al. Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. Case Rep Transplant. 2013;2013:196528doi: 10.1155/2013/196528.
Hevia, V., Gómez, V., Alvarez, S., Díez Nicolás, V., Gómez Del Cañizo, C., Orosa, A., Galeano Álvarez, C., & Burgos Revilla, F. J. (2013). Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. Case reports in transplantation, 2013196528. https://doi.org/10.1155/2013/196528
Hevia, Vital, et al. "Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients." Case reports in transplantation vol. 2013 (2013): 196528. doi: https://doi.org/10.1155/2013/196528
Hevia V, Gómez V, Alvarez S, Díez Nicolás V, Gómez Del Cañizo C, Orosa A, Galeano Álvarez C, Burgos Revilla FJ. Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. Case Rep Transplant. 2013;2013:196528. doi: 10.1155/2013/196528. Epub 2013 May 26. PMID: 23781380; PMCID: PMC3677624.
Copy Download .nbib Format: NLM
Percutaneous Renal Biopsy Prescreen Prior to Procedure.

Kidney international reports

Sosa Barrios RH, Burguera Vion V, Álvarez Nadal M, Villabón Ochoa P, Galeano Álvarez C, Rodríguez Mendiola N, Fernández Lucas M, Rivera Gorrín ME.
PMID: 32405594
Kidney Int Rep. 2020 Jan 30;5(5):731-733. doi: 10.1016/j.ekir.2020.01.013. eCollection 2020 May.

No abstract available.

Cite
Sosa Barrios RH, Burguera Vion V, Álvarez Nadal M, et al. Percutaneous Renal Biopsy Prescreen Prior to Procedure. Kidney Int Rep. 2020;5(5):731-733doi: 10.1016/j.ekir.2020.01.013.
Sosa Barrios, R. H., Burguera Vion, V., Álvarez Nadal, M., Villabón Ochoa, P., Galeano Álvarez, C., Rodríguez Mendiola, N., Fernández Lucas, M., & Rivera Gorrín, M. E. (2020). Percutaneous Renal Biopsy Prescreen Prior to Procedure. Kidney international reports, 5(5), 731-733. https://doi.org/10.1016/j.ekir.2020.01.013
Sosa Barrios, R Haridian, et al. "Percutaneous Renal Biopsy Prescreen Prior to Procedure." Kidney international reports vol. 5,5 (2020): 731-733. doi: https://doi.org/10.1016/j.ekir.2020.01.013
Sosa Barrios RH, Burguera Vion V, Álvarez Nadal M, Villabón Ochoa P, Galeano Álvarez C, Rodríguez Mendiola N, Fernández Lucas M, Rivera Gorrín ME. Percutaneous Renal Biopsy Prescreen Prior to Procedure. Kidney Int Rep. 2020 Jan 30;5(5):731-733. doi: 10.1016/j.ekir.2020.01.013. eCollection 2020 May. PMID: 32405594; PMCID: PMC7210601.
Copy Download .nbib Format: NLM
[Renal allograft transplant vascular complications. Diagnostic and treatment.].

Archivos espanoles de urologia

Gómez Dos Santos V, Hevia Palacios V, Galeano Álvarez C, Olavarría Delgado A, Díez Nicolás V, Jiménez Álvaro S, Álvarez Rodríguez S, Lorca Álvaro J, Del Cristo Artiles Medina A, Mata Alcaraz M, Burgos Revilla FJ.
PMID: 34851316
Arch Esp Urol. 2021 Dec;74(10):1013-1028.

Vascular complications remain common after renal transplantation, occurring in 3% to 15% of patients. These complications can compromise graft function,with graft loss rates ranging from 12.6 to 66.7%.Vascular abnormalities of the graft, specifically the presence of multiple vessels, represent...

Cite
Gómez Dos Santos V, Hevia Palacios V, Galeano Álvarez C, et al. Complicaciones vasculares del trasplante renal. Diagnóstico y tratamiento. [Renal allograft transplant vascular complications. Diagnostic and treatment.]. Arch Esp Urol. 2021;74(10):1013-1028
Gómez Dos Santos, V., Hevia Palacios, V., Galeano Álvarez, C., Olavarría Delgado, A., Díez Nicolás, V., Jiménez Álvaro, S., Álvarez Rodríguez, S., Lorca Álvaro, J., Del Cristo Artiles Medina, A., Mata Alcaraz, M., & Burgos Revilla, F. J. (2021). Complicaciones vasculares del trasplante renal. Diagnóstico y tratamiento. [Renal allograft transplant vascular complications. Diagnostic and treatment.]. Archivos espanoles de urologia, 74(10), 1013-1028.
Gómez Dos Santos, Victoria, et al. "Complicaciones vasculares del trasplante renal. Diagnóstico y tratamiento." [Renal allograft transplant vascular complications. Diagnostic and treatment.]. Archivos espanoles de urologia vol. 74,10 (2021): 1013-1028.
Gómez Dos Santos V, Hevia Palacios V, Galeano Álvarez C, Olavarría Delgado A, Díez Nicolás V, Jiménez Álvaro S, Álvarez Rodríguez S, Lorca Álvaro J, Del Cristo Artiles Medina A, Mata Alcaraz M, Burgos Revilla FJ. Complicaciones vasculares del trasplante renal. Diagnóstico y tratamiento. [Renal allograft transplant vascular complications. Diagnostic and treatment.]. Arch Esp Urol. 2021 Dec;74(10):1013-1028. Spanish. PMID: 34851316.
Copy Download .nbib Format: NLM
[Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

Galeano Alvarez C, Quereda Rodríguez-Navarro C.
PMID: 20221224
Nefrologia. 2009;29(6):40-2. doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free.

No abstract available.

Cite
Galeano Alvarez C, Quereda Rodríguez-Navarro C. ¿Es el micofenolato de mofetilo superior a la ciclofosfamida intravenosa como tratamiento de inducción en la nefritis lúpica? [Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?]. Nefrologia. 2009;29(6):40-2doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free.
Galeano Alvarez, C., & Quereda Rodríguez-Navarro, C. (2009). ¿Es el micofenolato de mofetilo superior a la ciclofosfamida intravenosa como tratamiento de inducción en la nefritis lúpica? [Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 29(6), 40-2. https://doi.org/10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free
Galeano Alvarez, Cristina, and Quereda Rodríguez-Navarro, Carlos. "¿Es el micofenolato de mofetilo superior a la ciclofosfamida intravenosa como tratamiento de inducción en la nefritis lúpica?" [Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia vol. 29,6 (2009): 40-2. doi: https://doi.org/10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free
Galeano Alvarez C, Quereda Rodríguez-Navarro C. ¿Es el micofenolato de mofetilo superior a la ciclofosfamida intravenosa como tratamiento de inducción en la nefritis lúpica? [Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?]. Nefrologia. 2009;29(6):40-2. doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free. Spanish. PMID: 20221224.
Copy Download .nbib Format: NLM
[Does delayed renal function affect graft and patient survival?].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

Fernández Rodríguez AM, Galeano Alvarez C, Marcén Letosa R.
PMID: 20221237
Nefrologia. 2009;29(6):82-4. doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free.

No abstract available.

Cite
Fernández Rodríguez AM, Galeano Alvarez C, Marcén Letosa R. ¿Influye la función renal retrasada en la supervivencia del injerto y del paciente? [Does delayed renal function affect graft and patient survival?]. Nefrologia. 2009;29(6):82-4doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free.
Fernández Rodríguez, A. M., Galeano Alvarez, C., & Marcén Letosa, R. (2009). ¿Influye la función renal retrasada en la supervivencia del injerto y del paciente? [Does delayed renal function affect graft and patient survival?]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 29(6), 82-4. https://doi.org/10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free
Fernández Rodríguez, Ana María, et al. "¿Influye la función renal retrasada en la supervivencia del injerto y del paciente?" [Does delayed renal function affect graft and patient survival?]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia vol. 29,6 (2009): 82-4. doi: https://doi.org/10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free
Fernández Rodríguez AM, Galeano Alvarez C, Marcén Letosa R. ¿Influye la función renal retrasada en la supervivencia del injerto y del paciente? [Does delayed renal function affect graft and patient survival?]. Nefrologia. 2009;29(6):82-4. doi: 10.3265/NEFROLOGIA.2009.29.S.E.noID.36.free. Spanish. PMID: 20221237.
Copy Download .nbib Format: NLM
Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated with Antithymocyte Globulin: A Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, Facundo C, Redondo-Pachón D, Suñer M, López-Oliva MO, Yuste JR, Montejo M, Galeano-Álvarez C, Ruiz-San Millan JC, Los-Arcos I, Hernández D, Fernández-Ruiz M, Muñoz P, Valle-Arroyo J, Cano A, Rodríguez-Benot A, Crespo M, Rodelo-Haad C, Lobo-Acosta MA, Garrido-Gracia JC, Vidal E, Guirado L, Cantisán S, Torre-Cisneros J.
PMID: 34228099
Clin Infect Dis. 2021 Jun 22; doi: 10.1093/cid/ciab574. Epub 2021 Jun 22.

BACKGROUND: Antiviral prophylaxis is recommended in cytomegalovirus (CMV)-seropositive kidney transplant (KT) recipients receiving antithymocyte globulin (ATG) as induction. An alternative strategy of premature discontinuation of prophylaxis after CMV-specific cell-mediated immunity (CMV-CMI) recovery (immunoguided prevention) has not been studied. The...

Cite
Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, et al. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated with Antithymocyte Globulin: A Randomized Clinical Trial. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab574.
Páez-Vega, A., Gutiérrez-Gutiérrez, B., Agüera, M. L., Facundo, C., Redondo-Pachón, D., Suñer, M., López-Oliva, M. O., Yuste, J. R., Montejo, M., Galeano-Álvarez, C., Ruiz-San Millan, J. C., Los-Arcos, I., Hernández, D., Fernández-Ruiz, M., Muñoz, P., Valle-Arroyo, J., Cano, A., Rodríguez-Benot, A., Crespo, M., Rodelo-Haad, C., Lobo-Acosta, M. A., Garrido-Gracia, J. C., Vidal, E., Guirado, L., Cantisán, S., & Torre-Cisneros, J. (2021). Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated with Antithymocyte Globulin: A Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab574
Páez-Vega, Aurora, et al. "Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated with Antithymocyte Globulin: A Randomized Clinical Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab574
Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, Facundo C, Redondo-Pachón D, Suñer M, López-Oliva MO, Yuste JR, Montejo M, Galeano-Álvarez C, Ruiz-San Millan JC, Los-Arcos I, Hernández D, Fernández-Ruiz M, Muñoz P, Valle-Arroyo J, Cano A, Rodríguez-Benot A, Crespo M, Rodelo-Haad C, Lobo-Acosta MA, Garrido-Gracia JC, Vidal E, Guirado L, Cantisán S, Torre-Cisneros J. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated with Antithymocyte Globulin: A Randomized Clinical Trial. Clin Infect Dis. 2021 Jun 22; doi: 10.1093/cid/ciab574. Epub 2021 Jun 22. PMID: 34228099.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries